Rhythm Pharmaceuticals Presents First Patient And Caregiver Reported Experiences From Phase 2 Trial Of Setmelanotide In Hypothalamic Obesity At ENDO 2024

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews 

- Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications -

- Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3 2024 -

- Preclinical data demonstrated potential of RM-718 to reduce body weight and hunger -

- Additional posters feature design of Phase 1 trial of RM-718 and real-world RESTORE study -